ArticleClinical rheumatology2026
Rheumatic disease in Canada's Northwest Territories: baseline review and comparative insights.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study captures baseline demographic and rheumatologic history of patients from Canada's Northwest Territories (NWT) to improve disease burden understanding, identify potential at-risk populations, and highlight care gaps in a unique and underserved population.
methodsIn this descriptive study, we collected retrospective data on patients referred from the NWT to Edmonton, Alberta, in 2022-2023, when all established and newly referred rheumatology patients from this region were redirected to receive care in Edmonton. Diagnoses were compared to a 2022-2023 Edmonton rheumatology new-patient cohort.
resultsThere were 425 patients (70% female) representing 30 communities. Of the 250 patients with documented ethnicity, 69.6%, 25.6%, and 4.8% were of Indigenous, White, and Other descent (including people of Asian and African descent), respectively. The most frequent inflammatory rheumatologic diagnoses among new referrals were rheumatoid arthritis (27.8%), gout (13.9%), and psoriatic arthritis and ankylosing spondylitis (11.1% each, vs. ~ 7% each in the Edmonton-based cohort). There were no new vasculitis cases in the NWT cohort compared to 9.2% of new diagnoses in the Edmonton cohort. Twenty-one percent of patients missed their appointments, and 43% of previously established patients had active disease.
conclusionThis represents the broadest epidemiologic dataset for NWT patients with rheumatologic diseases, with higher observed proportion of ankylosing spondylitis and psoriatic arthritis and lower observed proportion of vasculitis, compared to the Edmonton cohort. NWT patients face unique barriers around geographic location, transportation, and care delays, compounded by active disease that may disproportionately affect female and Indigenous patients. Key Points • This study provides the broadest epidemiologic dataset of patients with rheumatologic diseases in the Northwest Territories and is the first to comprehensively differentiate between various rheumatologic diseases seen in this population. • There appears to be a higher observed proportion of psoriatic arthritis and ankylosing spondylitis, as well as a lower observed proportion of vasculitis, in patients from the NWT. This may reflect the heterogeneity of the population as well as heterogeneity among different Indigenous groups, but confirming and explaining these patterns requires further exploration. • This study further re-emphasizes known barriers that patients from the NWT face, including geographic location, transportation access, and delays to specialist care, all compounded by active disease that frequently requires medications that can only be prescribed by the respective specialist. • These limitations may disproportionately affect female and Indigenous patients.
Indexed as
Identifiers
42260210What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.